Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment…
Articles by Alice Melão
Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease…
Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients…
A new method that selects and isolates malignant myeloma cells based on their size and molecular markers enables more precise…
P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from…
A new antibody targeting the BCMA protein — called SEA-BCMA — has shown promising effectiveness and safety results in animal…
Multiple myeloma patients in China may soon have access to an injectable formulation of melphalan, called Evomela, as…
The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing…
Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when…
PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food…